Colossal Spinoff Astromech Raises $20M as AI Biotech Explodes
anselm · x · 2026-08-21
Colossal Biosciences' spinout Astromech announced a $20M raise at a $3.8B valuation, focusing on AI-assisted drug design and discovery. CEO Ben Lamm predicts a "Precambrian explosion" of new drugs and therapies driven by AI. The company notes that up to 50% of biodiversity is forecast to be lost in the next 25 years, arguing conservation efforts aren't moving fast enough. Colossal has raised $635M to date.
Related event: Astromech, Colossal Spinout, Raises $20M at $3.8B Valuation(2 posts)→
More from Venture
- SoftBank planning record $6.3B bond sale to fund OpenAI investments — tszzl · 2026-08-24
- Ben Thompson Deep Dive: Risks of US Winning AI Race and Funding Concerns — JosephJacks_ · 2026-08-24
- Etched Raises $1B Led by Jane Street to Validate Architecture-Agnostic AI Chips — TheTuringPost · 2026-08-24
- Indie dev scales app to $6k/week using hyperrealistic AI UGC — 0x_rxkvys · 2026-08-24
- Fable 5 Makes Up Only 6% of Anthropic Sales — rohanpaul_ai · 2026-08-24
- Whisper kills the moat: Gong's transcription fortress collapses against OpenAI — roxylezan · 2026-08-24